GlobeVerge
WORLD
Amid increased tariffs, Sun Pharma to invest, set up plant in US, signs deal
Sun Pharma signs MFN pricing deal with US government to extend affordable medicines to Medicaid programmes. Mumbai drugmaker to apply Most Favoured Nation pricing to future innovative launches. US delays Section 232 tariffs by 2 years.
GlobeSignal-AImedium certainty
- Why it matters
- Sun Pharma commits to Most Favoured Nation pricing on future innovative drugs sold through Medicaid, lowering costs for low-income beneficiaries eligible for the program.
- Most affected
- Medicaid enrollees — Access to Sun Pharma's future innovative drugs at discounted MFN-negotiated prices.
Sun Pharma — Gains US tariff relief and grounds to establish domestic manufacturing. - Likely next
- Whether Sun Pharma completes the US plant construction and when it begins operations.